The company grew in the high-single-digits in FY1Q24 driven by sales and pull-through from its Aible digital ecosystem.

The company grew in the mid-teens for the first half of 2023, driven by strength across its trauma portfolio and geographic regions.

This additional capital will bolster efforts to rapidly expand both commercial and technology initiatives for the company.

Surgical volumes are healthy while staffing and supply are improving slowly. Industry leaders expect volume tailwinds into 2024.

In the second quarter of 2023, the company took steps to stabilize its financial position and assess its strategic path forward.

The company’s orthopedic sales grew in the mid-teens for the second quarter of 2023 on the strength of favorable order timing.

The company’s MACI sales grew 27% in the second quarter of 2023 while both surgeon and biopsy trends point to sustained momentum.

The company notched its fifth consecutive quarter of record revenues in 2Q23, with growth over 30% due to increased demand and new products.

The company grew 40% in the second quarter of 2023 due to its sole focus on bunion surgery and its specialized sales force.

The company grew in the mid-teens for the second quarter of 2023 and raised full-year guidance despite tougher comps in the second half.